TSXV:CLAS.H - Post by User
Post by
flyingdjon Jun 23, 2018 4:40pm
252 Views
Post# 28219015
Biggest Catalyst to come on Wednesday June 27th
Biggest Catalyst to come on Wednesday June 27th ust an update- This next week could make history in the USA when the FDA meets on June 27th to approve Epidolex a CBD based epilepsy drug manufactured by GW pharmaceuticals. Previously, A FDA Advisory Committee announced unanimous support following a review of Epidolex. Epidiolex would be the first pharmaceutical formulation of purified, plant-based CBD approved by the FDA and the approval would bring still badly needed attention to the positive medical effects of derivatives of cannabis. This is a very big deal in terms of the legitimacy of medical cannabis use and opens many doorways to descheduling or rescheduling cannabis from schedule 1 status. The medical uses of Cannabis are many fold. This is the first of many cannabis based drugs up for review. Many of us are already looking toward other cannabis research companies going down the same path towards approval. KALYTERA THERAPEUTICS INC COM (KALY or KALTF: OTCQB) is one that I currently own because The U.S. FDA has recommended that Kalytera apply for both Breakthrough Therapy and Fast Track Designations for our CBD products for prevention and treatment of acute GVHD (graft vs host disease), each of which could accelerate the approval process for these products. Stay tuned, Times are changing fast.
https://ir.gwpharm.com/…/gw-pharmaceuticals-and-us-subsidiar…
https://kalytera.co/…/kalytera-provides-update-on-its-lead…/